H Komuro1, S Kaneko, M Kaneko, Y Nakanishi. 1. Department of Pediatric Surgery, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan. hiro-kom@md.tsukuba.ac.jp
Abstract
PURPOSE: The growth and metastasis of malignant tumors is largely dependent on angiogenesis. Angiogenic factors produced by tumor cells are known to promote tumor angiogenesis. The aim of this study was to investigate which angiogenic factor is the most important in the progression of neuroblastoma (NB). PROCEDURE: The relative expression levels of vascular endothelial growth factor-A (VEGF-A), VEGF-C, basic fibroblast growth factor (bFGF), and platelet-derived endothelial growth factor (PD-ECGF/TP) were studied in 28 NB tumor specimens by real-time quantitative reverse transcriptase/polymerase chain reaction (RT-PCR). The relationships between the expression of these four angiogenic factors and stage, patient age, primary site, MYCN copy number, and lymph node metastasis were analyzed. RESULTS: High VEGF-A expression was correlated with stage 4 disease (blood-borne metastasis). No relationship between VEGF-A expression and age, primary site, MYCN copy number, or lymph node metastasis was found. The expression of VEGF-C, bFGF, or PD-ECGF/TP showed no correlation with stage, age, primary site, MYCN copy number, or lymph node metastasis. CONCLUSIONS: Our findings suggest that VEGF-A, but not VEGF-C, bFGF, or PD-ECGF/TP, may be associated with progression of NB. VEGF-A could be a target for antiangiogenic therapy for disseminated NB.
PURPOSE: The growth and metastasis of malignant tumors is largely dependent on angiogenesis. Angiogenic factors produced by tumor cells are known to promote tumor angiogenesis. The aim of this study was to investigate which angiogenic factor is the most important in the progression of neuroblastoma (NB). PROCEDURE: The relative expression levels of vascular endothelial growth factor-A (VEGF-A), VEGF-C, basic fibroblast growth factor (bFGF), and platelet-derived endothelial growth factor (PD-ECGF/TP) were studied in 28 NB tumor specimens by real-time quantitative reverse transcriptase/polymerase chain reaction (RT-PCR). The relationships between the expression of these four angiogenic factors and stage, patient age, primary site, MYCN copy number, and lymph node metastasis were analyzed. RESULTS: High VEGF-A expression was correlated with stage 4 disease (blood-borne metastasis). No relationship between VEGF-A expression and age, primary site, MYCN copy number, or lymph node metastasis was found. The expression of VEGF-C, bFGF, or PD-ECGF/TP showed no correlation with stage, age, primary site, MYCN copy number, or lymph node metastasis. CONCLUSIONS: Our findings suggest that VEGF-A, but not VEGF-C, bFGF, or PD-ECGF/TP, may be associated with progression of NB. VEGF-A could be a target for antiangiogenic therapy for disseminated NB.
Authors: Jürgen Becker; Helena Pavlakovic; Fabian Ludewig; Fabiola Wilting; Herbert A Weich; Romulo Albuquerque; Jayakrishna Ambati; Jörg Wilting Journal: Clin Cancer Res Date: 2010-02-23 Impact factor: 12.531
Authors: Yvan H Chanthery; W Clay Gustafson; Melissa Itsara; Anders Persson; Christopher S Hackett; Matt Grimmer; Elise Charron; Slava Yakovenko; Grace Kim; Katherine K Matthay; William A Weiss Journal: Sci Transl Med Date: 2012-01-04 Impact factor: 17.956
Authors: Kathrin Niemöller; Christian Jakob; Ulrike Heider; Ivana Zavrski; Jan Eucker; Olaf Kaufmann; Kurt Possinger; Orhan Sezer Journal: J Cancer Res Clin Oncol Date: 2003-04-17 Impact factor: 4.553
Authors: Shakeel Modak; Brian H Kushner; Ellen Basu; Stephen S Roberts; Nai-Kong V Cheung Journal: Pediatr Blood Cancer Date: 2017-01-23 Impact factor: 3.167
Authors: Elizabeth A Beierle; Xiaojie Ma; Jerry E Stewart; Michael Megison; William G Cance; Elena V Kurenova Journal: Mol Carcinog Date: 2012-10-12 Impact factor: 4.784
Authors: Ivana Zavrski; Cord Naujokat; Kathrin Niemöller; Christian Jakob; Ulrike Heider; Corinna Langelotz; Claudia Fleissner; Jan Eucker; Kurt Possinger; Orhan Sezer Journal: J Cancer Res Clin Oncol Date: 2003-07-08 Impact factor: 4.553